BELLICUM PHARMACEUTICALS, INC

2023 Q4 Form 10-Q Financial Statement

#000162828023038953 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.900M
YoY Change -79.48%
Cash & Equivalents $5.900M
Short-Term Investments
Other Short-Term Assets $900.0K
YoY Change -40.4%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $6.848M
YoY Change -78.1%
LONG-TERM ASSETS
Property, Plant & Equipment $5.000K
YoY Change -70.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $5.000K
YoY Change -70.59%
TOTAL ASSETS
Total Short-Term Assets $6.848M
Total Long-Term Assets $5.000K
Total Assets $6.853M
YoY Change -78.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $526.0K
YoY Change -26.33%
Accrued Expenses $1.205M
YoY Change -60.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.200M
YoY Change -61.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.200M
Total Long-Term Liabilities $0.00
Total Liabilities $2.249M
YoY Change -60.87%
SHAREHOLDERS EQUITY
Retained Earnings -$591.6M
YoY Change 3.94%
Common Stock $570.0M
YoY Change -2.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$27.01M
YoY Change
Total Liabilities & Shareholders Equity $6.853M
YoY Change -78.09%

Cashflow Statement

Concept 2023 Q4 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston,
us-gaap Net Income Loss
NetIncomeLoss
-18776000 usd
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1450200
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
924000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1964000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
6848000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
23801000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22000 usd
CY2023Q3 us-gaap Assets
Assets
6853000 usd
CY2022Q4 us-gaap Assets
Assets
23823000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
526000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
486000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1205000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2477000 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
518000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
809000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2249000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3772000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
31618000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
18036000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9784677 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9716931 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8682447 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8614701 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
98000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
87000 usd
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
67746 shares
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
67746 shares
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-354000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-591606000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-27014000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2015000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001358403
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
BELLICUM PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
3730 Kirby Drive,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1200,
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77098
dei City Area Code
CityAreaCode
281
dei Local Phone Number
LocalPhoneNumber
454-3424
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9716931 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5909000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21837000 usd
CY2023Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
15000 usd
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
0 usd
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5056000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5056000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
569904000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
582763000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-354000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-575425000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6853000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23823000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1008000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
263000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6850000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12286000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16425000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1511000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1315000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5208000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4216000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1774000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8165000 usd
us-gaap Operating Expenses
OperatingExpenses
17494000 usd
us-gaap Operating Expenses
OperatingExpenses
20641000 usd
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1000 usd
CY2022Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1000 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-773000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7165000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16485000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-19641000 usd
CY2023Q3 us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
2000 usd
CY2022Q3 us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
11000 usd
us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
10000 usd
us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
38000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5000 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
59000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-291000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-827000 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3000 usd
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3000 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-48000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
304000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
865000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-763000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7213000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16181000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-763000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-763000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7213000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7213000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16181000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-16181000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18776000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18776000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30904808 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30904808 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30831161 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30831161 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30858466 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30858466 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30826683 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30826683 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-763000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7213000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16181000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18776000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-10000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-15000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-763000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7223000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16181000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18791000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2015000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
559000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 blcm Stock Issued And Pre Funded Warrant Exercises During Period Value
StockIssuedAndPreFundedWarrantExercisesDuringPeriodValue
0 usd
CY2023Q1 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
4528000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8066000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-10020000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
59000 usd
CY2023Q2 blcm Stock Issued And Pre Funded Warrant Exercises During Period Value
StockIssuedAndPreFundedWarrantExercisesDuringPeriodValue
0 usd
CY2023Q2 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
4527000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7352000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-21840000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
116000 usd
CY2023Q3 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
4527000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-763000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-27014000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
24395000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
599000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q1 blcm Stock Issued And Pre Funded Warrant Exercises During Period Value
StockIssuedAndPreFundedWarrantExercisesDuringPeriodValue
0 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7565000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
17429000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
611000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4003000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
14037000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
685000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7223000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
7499000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16181000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18776000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
734000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1895000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-291000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-827000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
15000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
795000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1040000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
241000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
40000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
624000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1272000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-761000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15939000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18872000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000 usd
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
15000 usd
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-15000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15928000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18901000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21837000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47657000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5909000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28756000 usd
blcm Number Of Wholly Owned Subsidiaries Formed
NumberOfWhollyOwnedSubsidiariesFormed
1 subsidiary
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-591600000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-575400000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5900000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> interim condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. Actual results could differ from those estimates.</span></div>
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8000 usd
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
89000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
264000 usd
CY2023Q3 blcm Accrued Patient Treatment Costs Current
AccruedPatientTreatmentCostsCurrent
2000 usd
CY2022Q4 blcm Accrued Patient Treatment Costs Current
AccruedPatientTreatmentCostsCurrent
675000 usd
CY2023Q3 blcm Accrued Clinical Research Costs Current
AccruedClinicalResearchCostsCurrent
494000 usd
CY2022Q4 blcm Accrued Clinical Research Costs Current
AccruedClinicalResearchCostsCurrent
841000 usd
CY2023Q3 blcm Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
105000 usd
CY2022Q4 blcm Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
434000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
373000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
207000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
142000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
56000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1205000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2477000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10883193 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14154122 shares
CY2019Q3 blcm Proceeds From Public Offering
ProceedsFromPublicOffering
53800000 usd
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11200000 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
33294260 shares
CY2023Q3 blcm Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
33294260 shares
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
blcm Numberof Sharebased Compensation Plans
NumberofSharebasedCompensationPlans
5 plan
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
116000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
685000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
734000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1895000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
100000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y2M12D
CY2022Q4 blcm Number Of License Agreements Terminated
NumberOfLicenseAgreementsTerminated
2 licenseagreement

Files In Submission

Name View Source Status
0001628280-23-038953-index-headers.html Edgar Link pending
0001628280-23-038953-index.html Edgar Link pending
0001628280-23-038953.txt Edgar Link pending
0001628280-23-038953-xbrl.zip Edgar Link pending
a2023q3exhibit311.htm Edgar Link pending
a2023q3exhibit321.htm Edgar Link pending
blcm-20230930.htm Edgar Link pending
blcm-20230930.xsd Edgar Link pending
ex101amendmenttoconsulting.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
blcm-20230930_cal.xml Edgar Link unprocessable
blcm-20230930_def.xml Edgar Link unprocessable
blcm-20230930_lab.xml Edgar Link unprocessable
blcm-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
blcm-20230930_htm.xml Edgar Link completed